adenoviru
type
wide
use
experiment
clinic
gene
deliveri
oncolog
cardioangiolog
regen
medicin
also
use
vaccin
replic
nonrepl
adenovirus
shown
safe
vector
numer
clinic
howev
seriou
concern
regard
safeti
vector
aros
clinic
trial
halt
respons
fatal
advers
effect
ornithinetranscarbamylasedefici
patient
therefor
comprehens
understand
virolog
biolog
featur
defin
infect
possibl
toxic
differ
individu
urgent
requir
immunosuppress
occur
variou
type
patient
includ
infect
human
immunodefici
viru
hiv
recipi
organ
transplant
patient
gener
character
increas
distinct
suscept
variou
type
pathogen
depend
natur
immun
howev
behaviour
includ
biodistribut
resid
time
vector
context
immunodefici
poorli
understood
previous
construct
replicationcompet
vaccinia
tiantan
strain
infect
model
use
vivo
bioluminesc
imag
bli
method
found
immunodefici
rat
suscept
vaccinia
viru
spragu
dawley
sd
rat
also
display
prolong
bli
technolog
advantag
rapid
simplic
quantit
precis
allow
dissemin
clearanc
viral
vector
intact
live
anim
care
aim
studi
character
risk
associ
differ
mode
deliveri
especi
immunodefici
host
identifi
mechan
underli
result
immunopatholog
therefor
monitor
biodistribut
metabol
replicationincompet
express
firefli
luciferas
real
time
live
mice
rat
without
immunodefici
immunodefici
rat
gener
previous
resembl
immunodefici
human
mice
rat
use
vector
safeti
evalu
like
rat
mice
defect
recombin
machineri
requir
develop
b
cell
anim
produc
nk
cell
innat
immun
cell
affect
immunodefici
mice
sensit
viral
infect
immunocompet
mice
luminesc
signal
detect
bli
method
brain
tissu
section
show
patholog
find
mice
addit
tumour
necrosi
factor
interferon
relat
cytokin
storm
occur
mice
infect
intravascularli
level
cytokin
storm
correl
patholog
chang
liver
brain
test
verifi
b
cell
develop
homozyg
mice
use
flow
cytometri
identifi
variou
white
blood
cell
popul
peripher
blood
detect
significantli
reduc
number
helper
cell
mice
compar
wildtyp
mice
develop
cytotox
cell
also
block
mice
addit
fail
detect
b
cell
peripher
blood
mice
result
indic
matur
b
cell
produc
gene
knock
howev
observ
number
natur
killer
nk
cell
increas
mice
compar
wildtyp
mice
supplementari
fig
increas
nk
cell
may
compens
mechan
strengthen
immun
system
matur
b
cell
abolish
gene
knockout
commonli
administ
vaccin
vector
intramuscular
im
rout
gene
deliveri
vector
gene
therapi
intravascular
iv
rout
document
distribut
kinet
immunocompet
immunodefici
mous
model
anim
inocul
plaqueform
unit
pfu
kg
im
iv
rout
express
bioluminesc
luciferas
protein
bli
use
monitor
progress
site
degre
express
real
time
base
detect
luciferas
bioluminesc
vivo
luminesc
signal
visibl
inocul
site
im
iv
inject
abdomen
earli
h
administr
fig
b
left
suggest
bioluminesc
signal
gener
strong
enough
show
distribut
even
earli
stage
dissemin
day
peak
luminesc
intens
greatest
system
dissemin
observ
extend
abdomen
limb
head
mice
infect
via
iv
rout
howev
observ
rapid
damp
luciferas
express
wildtyp
mice
almost
clear
day
postinocul
regardless
rout
deliveri
im
iv
interestingli
luciferas
express
inject
im
persist
increas
continu
mice
end
experi
day
system
dissemin
observ
fig
left
without
clearanc
cell
cell
b
cell
luciferas
signal
significantli
stronger
persist
mice
regardless
inocul
rout
p
fig
b
right
data
indic
cell
b
cell
essenti
clearanc
administ
either
im
iv
rout
determin
bioluminesc
distribut
vivo
variou
organ
tissu
mice
dissect
analys
perfus
luciferin
day
postinocul
im
inocul
group
bioluminesc
signal
detect
tissu
around
inocul
site
includ
lymph
node
muscl
skin
liver
reflect
dissemin
kinet
muscl
liver
fig
judg
live
imag
biodistribut
ivinocul
wider
mice
mice
especi
limb
mouth
howev
bioluminesc
signal
differ
dissect
organ
limb
mouth
luminesc
detect
liver
spleen
lung
fig
indic
inocul
blood
iv
administr
accumul
rapidli
liver
spread
organ
rat
gener
appli
transcript
activatorlik
effector
nucleas
talen
technolog
observ
matur
b
cell
howev
anim
nk
cell
sd
rat
supplementari
fig
administr
pfukg
via
im
iv
rout
initi
local
system
dissemin
rat
similar
mice
rat
suscept
immunocompet
sd
rat
display
stronger
luminesc
signal
longer
resid
time
fig
b
left
clear
differ
iv
im
deliveri
rout
term
biodistribut
resid
time
infect
im
rout
distribut
wider
rat
sd
rat
howev
distribut
pattern
similar
two
rat
strain
administr
iv
rout
notabl
luciferas
signal
significantli
stronger
persist
rat
infect
iv
rout
sd
rat
p
fig
right
notabl
small
proport
sd
rat
infect
iv
rout
display
infect
spleen
rat
display
infect
liver
fig
vaccin
antigen
clearanc
predominantli
depend
adapt
immun
respons
therefor
strike
differ
profil
wildtyp
immunodefici
mice
might
relat
magnitud
cellular
immun
respons
cytokin
dysregul
increas
risk
associ
inocul
immunodefici
mice
examin
magnitud
cellular
respons
induc
immunodefici
mice
wildtyp
mice
notabl
mice
show
clearanc
cell
vivo
least
day
im
iv
inject
mani
proinflammatori
cytokin
blood
includ
inflammatori
cytokin
interleukin
il
granulocytemacrophag
colonystimul
factor
gmcsf
chemokin
monocyt
chemoattract
protein
measur
day
day
inocul
cytokin
level
show
littl
chang
mice
inocul
although
level
express
mice
trend
lower
day
postinocul
differ
reach
statist
signific
interestingli
mice
significantli
lower
express
level
mice
p
fig
possibl
due
lack
matur
b
lymphocyt
mice
expect
level
significantli
higher
mice
mice
p
fig
c
howev
although
level
tend
higher
mice
inocul
differ
reach
statist
signific
compar
effect
iv
im
administr
although
level
trend
higher
iv
group
im
group
especi
mice
differ
statist
signific
combin
compensatori
nk
cell
increas
mice
detect
flow
cytometri
data
suggest
innat
immun
respons
increas
prolong
mice
investig
potenti
risk
inocul
mice
bodi
weight
administr
monitor
patholog
chang
analys
signific
differ
detect
bodi
weight
gain
ivinfect
iminfect
mice
p
fig
howev
bodi
weight
gain
ivinfect
mice
significantli
lower
group
p
fig
system
histopatholog
examin
perform
mani
tissu
includ
brain
heart
liver
spleen
lung
kidney
intestin
thymu
muscl
testisovari
patholog
chang
observ
mice
fig
mice
fig
immunocompet
immunodefici
mice
inocul
via
im
rout
fig
f
therefor
im
rout
rel
safe
use
inocul
vaccin
howev
ivinocul
group
display
inflammatori
sign
liver
fig
h
upper
moreov
glial
nodul
form
oligodendrocyt
increas
brain
immunodefici
mice
inocul
via
iv
rout
contrast
chang
found
brain
mice
infect
via
iv
rout
fig
h
lower
alt
cytosol
enzym
mainli
exist
liver
ast
primarili
present
mitochondria
cytoplasm
liver
hepatocyt
damag
alt
ast
leak
circul
level
enzym
increas
serum
iv
administr
mice
increas
serum
alanin
aminotransferas
alt
fig
aspart
aminotransferas
ast
fig
activ
compar
control
mice
p
signific
differ
within
im
inocul
mice
fig
j
show
bli
valuabl
tool
visual
distribut
clearanc
cell
viru
administ
im
iv
rout
live
mice
rat
without
immunodefici
signific
advanc
toward
develop
therapi
vaccin
improv
extend
understand
immunopatholog
context
preclin
drug
safeti
evalu
rat
believ
higher
similar
human
provid
predict
use
experiment
data
pharmaceut
compani
use
rat
larg
proport
mandatori
toxic
rat
gener
talen
technolog
previous
use
evalu
toxic
biodistribut
immunodefici
studi
found
wide
dissemin
mice
rat
suggest
two
rodent
speci
differ
predict
outcom
human
howev
speci
distribut
resid
time
immunodefici
anim
differ
immunocompet
one
suggest
use
caution
variou
group
immunosuppress
patient
consider
seriou
advers
effect
expect
patient
consist
adenoviru
ubiquit
caus
gener
mild
selflimit
infect
immunocompet
adult
lead
seriou
often
lifethreaten
ill
solidorgan
transplant
recipi
aid
shown
iv
administr
halflif
min
normal
mice
clear
blood
within
h
viru
accumul
liver
elimin
kupffer
cell
within
studi
peak
level
transgen
express
significantli
higher
kinet
viral
clearanc
significantli
slower
b
celldefici
mice
wildtyp
mice
infect
via
either
iv
im
rout
therefor
specul
b
cell
play
import
role
clearanc
viru
specif
role
b
cell
primari
infect
somewhat
controversi
although
mice
lack
cell
b
cell
die
influenza
infect
mice
lack
cell
b
cell
howev
lee
et
al
show
mice
lack
b
cell
succumb
influenza
infect
despit
infiltr
larger
number
convent
assay
interact
involv
replicationcompet
replicationdefect
human
adenovirus
perform
pcr
southern
blot
immunohistochem
method
howev
requir
larg
number
anim
euthan
obtain
statist
meaning
data
multipl
time
simplifi
process
viral
vector
evalu
use
bli
monitor
dissemin
dynam
local
unexpect
anatom
site
anim
measur
firefli
luciferas
express
other
also
shown
signific
correl
photoemiss
viral
load
vivo
demonstr
mani
advantag
bli
includ
abil
imag
anim
repeatedli
ethic
econom
found
spread
liver
within
day
im
administr
report
previous
deliv
muscl
may
infect
antigenpres
cell
resid
traffic
howev
escap
perivascular
space
system
circul
via
vasa
vasorum
lymphat
im
contrast
iv
administr
rapidli
bind
circul
platelet
caus
activationaggreg
subsequ
entrap
liver
sinusoid
aggreg
taken
kupffer
cell
anticip
futur
develop
imag
strategi
detect
pathogen
also
cellular
tissuewid
reaction
host
studi
kadurugamuwa
et
al
use
multicolour
bioluminesc
track
bacteri
spread
identifi
host
neuron
injuri
key
step
toward
goal
monitor
host
current
evid
suggest
use
gene
therapi
vaccin
innat
immun
respons
respons
doselimit
toxic
adapt
immun
respons
elimin
infect
cell
limit
durat
transgen
found
mice
display
significantli
higher
level
cytokin
inocul
immunocompet
mice
posit
correl
viral
immunopatholog
level
also
report
clinic
case
anim
model
sever
acut
respiratori
syndrom
sar
releas
synthesi
tnf
turn
play
major
caus
role
patholog
chang
associ
iv
adenoviru
infus
well
role
induct
antivir
immun
produc
nk
cell
play
import
role
cellmedi
immun
broad
spectrum
intracellular
pathogen
also
activ
antigen
present
prime
releas
inflamm
associ
cytokin
storm
shown
begin
local
site
spread
throughout
bodi
via
system
therefor
specul
brain
patholog
immunodefici
mice
direct
toxic
effect
adenovector
deliveri
like
secondari
effect
inflamm
immun
respons
adenovector
consid
key
cytokin
drive
proinflammatori
notabl
hepat
injuri
detect
wildtyp
mice
muruv
show
neutrophil
acut
infiltr
liver
h
inject
immun
effector
cell
recruit
site
injuri
respons
chemokin
rant
signal
directli
correl
infiltr
inflammatori
cell
degre
hepat
similar
result
report
lieber
report
biphas
increas
serum
tnf
first
peak
contribut
macrophag
shortli
adenoviru
administr
second
major
peak
contribut
lymphocyt
sever
howev
decreas
significantli
infect
mice
produc
macrophag
activ
human
granulocyt
includ
neutrophil
eosinophil
basophil
may
lead
acut
neutrophil
research
requir
determin
whether
highlevel
express
cytokin
low
level
mice
caus
effect
observ
patholog
chang
moreov
dynam
cytokin
express
infect
vivo
also
investig
detect
transient
chang
cytokin
level
piti
data
cytokin
respons
histopatholog
conduct
rat
believ
conclus
robust
complement
addit
data
rat
pay
attent
problem
futur
studi
current
goal
vaccinologist
gene
therapist
creat
avoid
detect
immun
system
deleteri
side
effect
believ
focu
two
type
approach
first
dosag
control
find
indic
hepatotrop
doselimit
certain
threshold
dose
inject
satur
capac
kupffer
cell
adenoviru
uptak
lead
system
dissemin
particl
result
acut
hepatocellular
damag
potenti
infect
cell
type
secret
proinflammatori
cytokin
thu
exacerb
system
toxic
second
approach
involv
modifi
method
rout
deliveri
use
instanc
hydrodynam
inject
ultrasoundguid
intramyocardi
gene
deliveri
techniqu
local
deliv
low
vector
dose
directli
target
organ
reduc
system
dissemin
vector
inflammatori
respons
cytokin
flare
reduc
bodi
weight
gain
patholog
damag
suggest
possibl
risk
involv
use
gene
therapi
via
iv
rout
especi
immunodefici
popul
although
use
preclin
studi
gener
predict
rodent
studi
limit
applic
human
outcom
singl
anim
model
never
recapitul
aspect
human
viralvectorbas
gene
therapi
vaccin
model
advantag
disadvantag
adenovirusvector
vaccin
construct
base
variou
differ
system
studi
recombin
gener
use
creloxpbas
use
sever
vaccin
includ
hiv
gene
notabl
promot
overal
design
express
cassett
major
impact
toxic
distribut
vivo
therefor
safeti
recombin
product
gener
construct
system
must
evalu
futur
studi
addit
rel
data
obtain
older
anim
gene
therapi
predominantli
administ
adult
degener
tissuescel
summari
studi
test
resid
time
biodistribut
possibl
toxic
immunodefici
immunocompet
mice
rat
dose
equival
higher
end
reason
rang
human
found
ideal
rout
administr
im
even
immunodefici
anim
success
safe
treat
high
dose
vaccin
advers
effect
observ
anim
treat
iv
rout
use
previou
gene
therapi
applic
therefor
accord
previou
report
believ
vector
gener
safe
vaccin
gene
therapi
applic
howev
futur
research
focu
advers
effect
recipi
congenit
immunodefici
background
virusinduc
immunodefici
final
visual
infect
immunocompet
immunodefici
mice
rat
addit
altern
way
studi
adenovir
infect
conveni
sensit
requir
use
fewer
anim
use
firefli
luciferas
fluc
gene
deriv
plucf
kindli
provid
john
schiller
nation
cancer
institut
bethesda
md
usa
replicationincompet
construct
delet
viral
gene
use
creloxpbas
briefli
pcr
use
construct
recombin
shuttl
plasmid
cell
cotransfect
express
plasmid
contain
structur
gene
report
plasmid
construct
use
lipofectamin
invitrogen
carlsbad
ca
usa
recombin
adenoviru
contain
fluc
gene
acquir
crelox
recombin
cell
detect
b
nk
cell
fourweek
old
mice
multicolour
cytometr
analysi
perform
use
bd
facscalibur
flow
cytomet
becton
dickinson
franklin
lake
nj
usa
accord
manufactur
protocol
peripher
blood
collect
inner
canthu
mice
blood
deplet
erythrocyt
lyse
solut
bd
pharmingen
san
diego
ca
usa
white
blood
cell
examin
doubli
stain
antibodi
includ
isothiocyan
fitc
cat
pe
cat
apc
cat
cat
cat
antibodi
purchas
bd
pharmingen
mice
rat
use
studi
hous
handl
strictli
accord
guidelin
set
associ
assess
accredit
laboratori
anim
care
aaalac
frederick
md
usa
studi
protocol
approv
anim
care
use
committe
nation
institut
food
drug
control
nifdc
beij
china
fourweekold
mice
rat
wildtyp
mice
sd
rat
obtain
institut
laboratori
anim
resourc
nifdc
eight
group
mice
ten
per
group
rat
four
per
group
receiv
singl
dose
pfukg
suspend
pb
im
inocul
pfukg
suspend
pb
iv
tail
vein
inject
dose
equival
higher
end
reason
rang
mice
rat
examin
bli
h
day
day
day
day
day
day
postinfect
ten
addit
normal
anim
mice
use
neg
control
test
immunopatholog
mice
bodi
weight
monitor
record
mice
rat
human
euthan
isofluran
analys
biodistribut
tissu
day
postinfect
bioluminesc
imag
perform
ivi
lumina
seri
iii
imag
system
perkinelm
baltimor
md
usa
describ
brief
mice
rat
anesthet
success
intraperiton
inject
pelltobarbitalum
natricum
mgkg
bodi
weight
substrat
dluciferin
mgkg
bodi
weight
xenogencalip
corp
alameda
ca
usa
mice
rat
imag
min
later
imag
individu
tissu
mice
rat
dissect
rapidli
bioluminesc
quantifi
use
ivi
system
analys
tissu
ex
vivo
within
min
dissect
luminesc
acquir
exposur
time
region
interest
roi
analys
live
imag
softwar
calip
life
scienc
baltimor
md
usa
rel
intens
emit
light
present
pseudocolour
imag
colour
rang
red
intens
blue
least
intens
signal
emit
differ
roi
bodi
measur
present
total
flux
photonss
data
present
mean
valu
sem
plasma
separ
edtatr
blood
sampl
centrifug
g
min
cytokin
includ
tnf
gmcsf
quantifi
cytometr
bead
array
bd
bioscienc
facscalibur
cytomet
bd
bioscienc
method
use
previous
analyz
immunopatholog
differ
viral
infect
individu
cytokin
concentr
pgml
comput
standard
refer
curv
bd
bioscienc
fcap
array
softwar
accord
manufactur
protocol
inflammatori
cytokin
measur
simultan
differ
captur
bead
captur
bead
array
uniqu
fluoresc
coat
captur
antibodi
specif
singl
analyt
combin
differ
bead
mix
sampl
standard
mixtur
detect
antibodi
conjug
report
molecul
pe
incub
subsequ
wash
sampl
analys
flow
cytomet
tissu
includ
heart
lung
liver
spleen
kidney
intestin
thymu
skin
muscl
brain
dissect
mice
day
postinfect
fix
formalin
embed
paraffin
paraffin
section
thick
stain
haematoxylin
eosin
patholog
chang
observ
light
microscop
plasma
alanin
aminotransferas
alt
aspart
aminotransferas
ast
activ
measur
use
enzymelink
immun
sorbent
assay
elisa
kit
china
accord
manufactur
instruct
graph
gener
prism
softwar
graphpad
san
diego
ca
usa
differ
variou
cytokin
level
pre
postinfect
subgroup
differ
bioluminesc
intens
normal
subgroup
calcul
pair
ttest
p
valu
consid
statist
signific
